<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248855</url>
  </required_header>
  <id_info>
    <org_study_id>KAN-101-01</org_study_id>
    <nct_id>NCT04248855</nct_id>
  </id_info>
  <brief_title>Assessment of KAN-101 in Celiac Disease (ACeD)</brief_title>
  <official_title>A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anokion SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A safety study of KAN-101 in patients with celiac disease. The study has two parts:

        1. Part A - first in human study in which patients receive a single dose of KAN-101

        2. Part B - patients will receive three doses of either KAN-101 or placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study KAN-101-01 is a Phase 1, FIH study designed to evaluate the safety and tolerability of
      KAN-101 in patients with celiac disease on a gluten free diet (GFD).

      An overview of the two parts and proposed dose groups is given below:

        1. Part A (SAD): Patients will receive a single dose of KAN-101.

        2. Part B (MAD): Patients will receive three doses of either KAN-101 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or higher</measure>
    <time_frame>Up to 28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean of maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the last measurable time point (AUC last)</measure>
    <time_frame>Up to 15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive one dose of KAN-101 Dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive one dose of KAN-101 Dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive one dose of KAN-101 Dose C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive one dose of KAN-101 Dose D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All randomized patients will receive 3 doses of either KAN-101 Dose A or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All randomized patients will receive 3 doses of either KAN-101 Dose B or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All randomized patients will receive 3 doses of either KAN-101 Dose C or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAN-101</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>MAD Cohort 5</arm_group_label>
    <arm_group_label>MAD Cohort 6</arm_group_label>
    <arm_group_label>MAD Cohort 7</arm_group_label>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>MAD Cohort 5</arm_group_label>
    <arm_group_label>MAD Cohort 6</arm_group_label>
    <arm_group_label>MAD Cohort 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Adults aged 18 to 70 years inclusive

          2. Diagnosed with celiac disease based on positive serology (eg, tissue transglutaminase
             IgA antibody and/or deamidated gliadin peptide IgG) and intestinal histology
             consistent with â‰¥ Marsh Type II or with evidence of villous atrophy

          3. Has HLA-DQ2.5 genotype (HLA-DQA1*05 and HLA-DQB1*02) (homozygotes or heterozygotes)

          4. Has followed a GFD for &gt; 12 months immediately prior to study entry

          5. Negative for tTG and negative or weak positive for DGP-IgA/IgG during screening

          6. Male or female, and using at least 2 acceptable birth control methods or who are
             sterile or postmenopausal

          7. Capable of understanding and complying with protocol requirements

          8. Patient understands and has signed the informed consent form

        Key Exclusion Criteria:

          1. Refractory celiac disease

          2. Selective IgA deficiency

          3. Positive for HLA-DQ8 (DQA1*03, DQB1*0302)

          4. Previous treatment with tolerance-inducing therapies for celiac disease

          5. Known wheat allergy

          6. Part B only: History of hyperacute or prolonged symptoms following gluten exposure

          7. Uncontrolled or significant medical conditions (including active infections or chronic
             hepatitis) which, in the opinion of the Investigator, preclude participation

          8. History of dermatitis herpetiformis

          9. Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kanyos Bio, Inc.</last_name>
    <phone>+1 857-320-6607</phone>
    <email>clinicaltrials@anokion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innovative Medical Research of South Florida, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Parexel International- EPCU Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Michigan Clinical Research Center</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Double blind</keyword>
  <keyword>Multicenter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

